This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

US Psych Congress Annual
October 29th – November 2nd 2024, Boston, MA
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Bipolar Disorder
POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

Schizophrenia
POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

Schizophrenia
POSTER
Clinical Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Patients Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane, MD,1 Andrea B. Barthel, MS,2 Chenxue Liang,2 Zhengfan Wang,2 Elizabeth S. Nagelhout,2 Lauren N. Strand, PhD, MS,3 Michael J. Doane, PhD,3 Regina Grebla, PhD3

Schizophrenia
POSTER
Baseline Severity of Illness and Response to Treatment With Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data
AUTHOR(S)

John M. Kane, MD1 ; Martin Dunbar, PhD2 ; and James A. McGrory, PhD2

Schizophrenia
POSTER
Acute and Maintenance Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients With Acute Schizophrenia: A Post Hoc Analysis
AUTHOR(S)

Roger S. McIntyre,1 Desiree M. Matthews,2 Marni E. Harris,3 Christina Arevalo,3 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

Bipolar Disorder
Schizophrenia
POSTER
Study Retention Rates in the OLZ/SAM Phase 3 Clinical Program
AUTHOR(S)

René S. Kahn,1 Christina Arevalo,2 Marni E. Harris,2 David McDonnell3

Bipolar Disorder
Schizophrenia
ENCORE POSTER
Long-Term Safety and Efficacy of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon,1 René S. Kahn,2 Christina Arevalo,3 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

Schizophrenia
ENCORE POSTER
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
AUTHOR(S)

Lauren N. Strand, PhD, MS1 ; Michael J. Doane, PhD1 ; James A. McGrory, PhD1 ; Alejandro G. Hughes, MPH2 ; John Lauriello, MD3

Narcolepsy
ENCORE POSTER
The Burden of Living With Narcolepsy Patient Perspectives From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Wilbur P. Williams, III1

Narcolepsy
ENCORE POSTER
Safety and Pharmacodynamic Effects of the Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 1: A First-in-Human Phase 1 Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Angela D’Rozario,1 Craig Hopkinson,2 Jandira Ramos,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

Narcolepsy
ENCORE POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 2: An Initial Proof of Concept Phase 1b Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Shifang Liu,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

Narcolepsy
ENCORE POSTER
Clinical, Economic, and Humanistic Burden Associated With Narcolepsy: Results From a Systematic Literature Review
AUTHOR(S)

Michael J. Doane,1 Miranda Lauher-Charest,2 Gia Huynh,2 Kristen McCausland2